VERIFLO 25MCG/250MCG/DÁV Suspenze k inhalaci v tlakovém obalu Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

veriflo 25mcg/250mcg/dáv suspenze k inhalaci v tlakovém obalu

zentiva, k.s., praha array - 14181 salmeterol-xinafoÁt; 12768 flutikason-propionÁt - suspenze k inhalaci v tlakovém obalu - 25mcg/250mcg/dÁv - salmeterol a flutikason

VERIFLO 25MCG/50MCG/DÁV Suspenze k inhalaci v tlakovém obalu Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

veriflo 25mcg/50mcg/dáv suspenze k inhalaci v tlakovém obalu

zentiva, k.s., praha array - 14181 salmeterol-xinafoÁt; 12768 flutikason-propionÁt - suspenze k inhalaci v tlakovém obalu - 25mcg/50mcg/dÁv - salmeterol a flutikason

Bemrist Breezhaler Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - léky na obstrukční onemocnění dýchacích cest, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Atectura Breezhaler Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

atectura breezhaler

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - léky na obstrukční onemocnění dýchacích cest, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Seffalair Spiromax Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

seffalair spiromax

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - léky na obstrukční onemocnění dýchacích cest, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Enerzair Breezhaler Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - léky na obstrukční onemocnění dýchacích cest, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Zimbus Breezhaler Den Europæiske Union - tjekkisk - EMA (European Medicines Agency)

zimbus breezhaler

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - léky na obstrukční onemocnění dýchacích cest, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

MOMANOSE 50MCG/DÁV Nosní sprej, suspenze Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

momanose 50mcg/dáv nosní sprej, suspenze

sandoz s.r.o., praha array - 14957 monohydrÁt mometason-furoÁtu - nosní sprej, suspenze - 50mcg/dÁv - mometason

MOMMOX 0,05MG/DÁV Nosní sprej, suspenze Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

mommox 0,05mg/dáv nosní sprej, suspenze

sandoz s.r.o., praha array - 14957 monohydrÁt mometason-furoÁtu - nosní sprej, suspenze - 0,05mg/dÁv - mometason

RYALTRIS 25MCG/600MCG/DÁV Nosní sprej, suspenze Tjekkiet - tjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

ryaltris 25mcg/600mcg/dáv nosní sprej, suspenze

glenmark pharmaceuticals s.r.o., praha array - 14957 monohydrÁt mometason-furoÁtu; 16715 olopatadin-hydrochlorid - nosní sprej, suspenze - 25mcg/600mcg/dÁv - mometason, kombinace